Most neurologists treating Parkinson's patients were unaware of contaminants in medical cannabis products
A survey of neurologists treating Parkinson's disease found 65% were unaware of any contaminants in cannabis products, despite PD patients using cannabis at rates 1.5 to 2 times higher than the general population and being potentially more susceptible to environmental toxins.
Quick Facts
What This Study Found
The number of states including PD-related qualifying conditions for medical cannabis increased from 28 to 36 between 2019 and 2023. Among surveyed neurologists, 65% were unaware of any cannabis contaminants. Only 25% knew about pesticide contamination, 15% about toxic elements, and 15% about solvents. PD patients use cannabis at 25-40% compared to 18% in the general population.
Key Numbers
PD qualifying conditions: 28 to 36 states (2019-2023). PD-specific states: 14 to 16. Pain qualifying: 17 to 35 states. 45 neurologists surveyed, 44% response. 65% unaware of contaminants. 25% aware of pesticides. 15% aware of toxic elements/solvents. PD cannabis use: 25-40% vs 18% general population.
How They Did This
Two-part study: (1) regulatory analysis of PD-related qualifying conditions across US states from 2019-2023, and (2) online survey of 45 neurologists/movement disorder specialists with 44% response rate.
Why This Research Matters
Parkinson's patients may be uniquely vulnerable to cannabis contaminants because their neurological condition can be worsened by environmental toxins. If the physicians recommending or discussing cannabis with these patients are unaware of contamination risks, patients cannot make informed decisions.
The Bigger Picture
As medical cannabis access expands for neurological conditions, the gap between increasing patient use and physician knowledge about product safety represents a growing risk that extends beyond Parkinson's to all neurology patients.
What This Study Doesn't Tell Us
Very small survey sample (response from ~20 neurologists). Self-selected respondents. Nine states represented, not nationally comprehensive. Low response rate. Cannot determine whether physician awareness affects patient outcomes.
Questions This Raises
- ?Are cannabis contaminants actually worsening PD outcomes?
- ?Would physician education about cannabis product safety change prescribing behavior?
Trust & Context
- Key Stat:
- 65% of neurologists unaware of cannabis product contaminants
- Evidence Grade:
- Exploratory survey with very small sample. Highlights a knowledge gap but cannot quantify its clinical impact.
- Study Age:
- 2024 study
- Original Title:
- Cannabis use in Parkinson's disease: Patient access to medical cannabis and physician perspective on product safety.
- Published In:
- Neurotoxicology, 103, 198-205 (2024)
- Authors:
- Griffith, Symone T, Conrow, Kendra D, Go, Michael, McEntee, Mindy L, Daniulaityte, Raminta, Nadesan, Majia H, Swinburne, Mathew R, Shill, Holly A, Leung, Maxwell C K
- Database ID:
- RTHC-05353
Evidence Hierarchy
Watches what happens naturally without intervening.
What do these levels mean? →Frequently Asked Questions
What contaminants are found in cannabis?
Common contaminants include pesticides, heavy metals (lead, cadmium, arsenic), residual solvents from extraction processes, mold, bacteria, and mycotoxins. Testing requirements vary significantly between states.
Why are Parkinson's patients at special risk?
PD patients have compromised neurological function and may be more susceptible to neurotoxic contaminants. Their higher-than-average cannabis use rate increases cumulative exposure. Additionally, PD medication interactions with cannabis are poorly understood.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-05353APA
Griffith, Symone T; Conrow, Kendra D; Go, Michael; McEntee, Mindy L; Daniulaityte, Raminta; Nadesan, Majia H; Swinburne, Mathew R; Shill, Holly A; Leung, Maxwell C K. (2024). Cannabis use in Parkinson's disease: Patient access to medical cannabis and physician perspective on product safety.. Neurotoxicology, 103, 198-205. https://doi.org/10.1016/j.neuro.2024.05.008
MLA
Griffith, Symone T, et al. "Cannabis use in Parkinson's disease: Patient access to medical cannabis and physician perspective on product safety.." Neurotoxicology, 2024. https://doi.org/10.1016/j.neuro.2024.05.008
RethinkTHC
RethinkTHC Research Database. "Cannabis use in Parkinson's disease: Patient access to medic..." RTHC-05353. Retrieved from https://rethinkthc.com/research/griffith-2024-cannabis-use-in-parkinsons
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.